Lion Biotechnologies to Present at the 4th Annual Cancer Immunotherapy Conference
24 March 2014 - 11:00PM
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company
focused on the development and commercialization of novel cancer
immunotherapies based on tumor-infiltrating lymphocytes (TILs),
today announced that Chief Executive Officer Manish Singh, Ph.D.,
will be presenting at the 4th Annual Cancer Immunotherapy
Conference at the New York Academy of Medicine in New York City.
The presentation is scheduled for Thursday, March 27, 2014, at 9:00
am Eastern Time.
Additionally, Dr. Singh will be presenting on the following
panels:
12:00pm - 12:45pm: Autologous
Immunotherapies |
4:15pm - 4:45pm: Immunotherapies for Solid
Tumors |
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of
T-cells and engineered T-cells for the treatment of various
cancers. The company's lead product candidate is a
ready-to-infuse autologous T-cell therapy utilizing
tumor-infiltrating lymphocytes (TILs) for the treatment of patients
with Stage IV metastatic melanoma, and is based on a clinical CRADA
with the National Cancer Institute along with physician-sponsored
investigational therapy at the MD Anderson Cancer Center and the H.
Lee Moffitt Cancer & Research Institute. For more information,
please visit http://www.lionbio.com.
CONTACT: Investor Relations
The Trout Group
Gitanjali Jain Ogawa
646-378-2949
gogawa@troutgroup.com